Literature DB >> 22317771

Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients.

C M Choi1, S C Yang, H J Jo, S Y Song, Y J Jeon, T W Jang, D J Kim, S H Jang, S H Yang, Y D Kim, K H Lee, S J Jang, Y T Kim, D K Kim, D H Chung, L Kim, H S Nam, J H Cho, H J Kim, J S Ryu.   

Abstract

BACKGROUND: Biological complexity leads to significant variation in the survival of patients with stage I non-small-cell lung cancer (NSCLC). DNA damage response (DDR) pathways play a critical role in maintaining genomic stability and in the progression of NSCLC. Therefore, the development of a prognostic biomarker focusing on DDR pathways is an intriguing issue. PATIENTS AND METHODS: Expression of several proteins (ATM, ATMpS1981, γH2AX, 53BP1, 53BP1pS25, Chk2, Chk2pT68, MDC1, MDC1pS964, BRCA1pS1423, and ERCC1) and overall survival were investigated in 889 pathological stage I NSCLC patients.
RESULTS: Low expression of BRCA1pS1423 or ERCC1 was significantly associated with worse survival in the whole cohort of patients. Analysis performed based on histology revealed that low expression of γH2AX, Chk2pT68, or ERCC1 was a poor prognostic factor in squamous cell carcinoma patients [adjusted hazard ratio (aHR), Cox P: 1.544, 0.012 for γH2AX; 1.624, 0.010 for Chk2pT68; 1.569, 0.011 for ERCC1]. The analysis of the interaction between two proteins showed that this effect was more pronounced in squamous cell carcinoma patients. However, these effects were not detected in adenocarcinoma patients.
CONCLUSIONS: The proteins involved in DDR pathways exhibited differential expression between squamous cell carcinoma and adenocarcinoma and were important determinants of survival in stage I squamous cell carcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22317771     DOI: 10.1093/annonc/mdr606

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  11 in total

1.  Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer.

Authors:  Hongying Lv; Ting Han; Xiaoli Shi; Yasai Yao; Yongru Yao; Wensheng Qiu; Lu Yue; Jun Liang
Journal:  Med Oncol       Date:  2014-06-24       Impact factor: 3.064

2.  Multiplexed specific label-free detection of NCI-H358 lung cancer cell line lysates with silicon based photonic crystal microcavity biosensors.

Authors:  Swapnajit Chakravarty; Wei-Cheng Lai; Yi Zou; Harry A Drabkin; Robert M Gemmill; George R Simon; Steve H Chin; Ray T Chen
Journal:  Biosens Bioelectron       Date:  2012-11-27       Impact factor: 10.618

3.  ERCC1 and personalized medicine in lung cancer.

Authors:  Jeong Seon Ryu; Azra Memon; Seul-Ki Lee
Journal:  Ann Transl Med       Date:  2014-04

4.  ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.

Authors:  Matthias Villalobos; Piotr Czapiewski; Niels Reinmuth; Jürgen R Fischer; Stefan Andreas; Cornelius Kortsik; Monika Serke; Martin Wolf; Petra Neuser; Alexander Reuss; Philipp A Schnabel; Michael Thomas
Journal:  Med Oncol       Date:  2018-06-15       Impact factor: 3.064

5.  Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.

Authors:  Eszter Podmaniczky; Katalin Fábián; Judit Pápay; Rita Puskás; Márton Gyulai; József Furák; László Tiszlavicz; György Losonczy; József Tímár; Judit Moldvay
Journal:  Pathol Oncol Res       Date:  2014-09-07       Impact factor: 3.201

6.  ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

Authors:  Luc Friboulet; Ken André Olaussen; Jean-Pierre Pignon; Frances A Shepherd; Ming-Sound Tsao; Stephen Graziano; Robert Kratzke; Jean-Yves Douillard; Lesley Seymour; Robert Pirker; Martin Filipits; Fabrice André; Eric Solary; Florence Ponsonnailles; Angélique Robin; Annabelle Stoclin; Nicolas Dorvault; Frédéric Commo; Julien Adam; Elsa Vanhecke; Patrick Saulnier; Jürgen Thomale; Thierry Le Chevalier; Ariane Dunant; Vanessa Rousseau; Gwénaël Le Teuff; Elisabeth Brambilla; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2013-03-21       Impact factor: 91.245

7.  Prognostic significance of G2/M arrest signaling pathway proteins in advanced non-small cell lung cancer patients.

Authors:  Jing Wang; Yuhai Zhang; Shudi Xu; Weijie Li; Zhangqin Chen; Zhe Wang; Xinpeng Han; Yiling Zhao; Shengqing Li
Journal:  Oncol Lett       Date:  2015-01-02       Impact factor: 2.967

8.  Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).

Authors:  Vassiliki Kotoula; Dimitrios Krikelis; Vasilios Karavasilis; Triantafillia Koletsa; Anastasia G Eleftheraki; Despina Televantou; Christos Christodoulou; Stefanos Dimoudis; Ippokratis Korantzis; Dimitrios Pectasides; Konstantinos N Syrigos; Paris A Kosmidis; George Fountzilas
Journal:  BMC Cancer       Date:  2012-08-06       Impact factor: 4.430

9.  Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer.

Authors:  Daniel Richard Gomez; Lauren Averett Byers; Monique Nilsson; Lixia Diao; Jing Wang; Lerong Li; Pan Tong; Mia Hofstad; Babita Saigal; Ignacio Wistuba; Neda Kalhor; Stephen Swisher; Youhong Fan; Waun Ki Hong; Milind Suraokar; Carmen Behrens; Cesar Moran; John Victor Heymach
Journal:  Oncotarget       Date:  2018-01-30

10.  Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Thorsten Derlin; Natalia Bogdanova; Fiona Ohlendorf; Dhanya Ramachandran; Rudolf A Werner; Tobias L Ross; Hans Christiansen; Frank M Bengel; Christoph Henkenberens
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.